Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Joshi, Samir ; Telang, Rahul ; Tambe, Muralidhar ; Havaldar, Rajesh ; Sane, Manasi ; Shaikh, Afshan ; Roy, Cherry ; Yathati, Kireet ; Sonawale, Sanjaykumar ; Borkar, Rupalee ; Magar, Rahul ; Bhitkar, Harshal ; Shitole, Satish ; Nakate, Leena ; Kudrimoti, Jyoti ; Mave, Vidya
• Description:
  We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confirmed rhino-sino-orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis.
• Subjects:
  Coronavirus Infections Covid-19 Humans Mucormycosis Orbital Diseases Pandemics Retrospective Studies Sars-Cov-2
• Source:
  Emerg Infect Dis. 2022; 28(1):1-8
• Pubmed ID:
  34586055
• Pubmed Central ID:
  PMC8714213
• Document Type:
  Journal Article
• Place as Subject:
  India
• Volume:
  28
• Issue:
  1
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:dfe4feb446687492ac279b4cdd98e3891ac0be28eae5bce3e7a124b939c98209
• Download URL:
  https://stacks.cdc.gov/view/cdc/113340/cdc_113340_DS1.pdf
• File Type:
  [PDF - 1.66 MB ]